Skip to main content

Table 1 Patient demographics and baseline characteristics

From: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors

(NEO-201)

Variable

Trait

Number

Total

Patients

17

Gender

Female

11

Male

6

Race

White

15

African American

2

Native Hawaiian or other

0

Pacific Islander

0

Other

0

Ethnicity

Hispanic

0

Non-Hispanic

17

Age

18 – 30

0

31 – 40

1

41 – 50

4

51 – 60

4

61 – 70

5

71 – 80

2

 > 80

1

Disease Histology

Adenocarcinoma of pancreas

4

Colorectal cancer

11

Breast cancer

2